Mavrostobart
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Mavrostobart, covering 2025-01-31 to 2025-01-31. Get the full timeline:
Most recent: Clinical Trial Update: Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) [Phase 1, Phase 2]